Search

everythinglearnresearchcommunity

for

Search:↓

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Healthcare workers with COVID-19 reported more long-term symptoms, and physical activity may help reduce some of these symptoms.

The flap effectively sealed leaks and served as a barrier, with minor complications, for anterior skull base surgery.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Healthcare workers with a positive COVID-19 test were more likely to report long-COVID symptoms.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.

Selenium levels are similar in healthy people from both high and low NPC risk areas.

Nasopharyngeal carcinoma is a common cancer in Indonesia, with risk factors including genetics, diet, and Epstein-Barr virus, and is treated with advanced radiotherapy.

Pertussis toxin may contribute to hair loss in alopecia areata.

Stem cell research and regenerative medicine have made significant advancements in treating various diseases and conditions.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Ritlecitinib effectively treats alopecia areata with manageable side effects.

Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Cepharanthine is safe but not clearly effective in speeding up COVID-19 recovery.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.